GEORGE P RODGERS, MD
Osteopathic Medicine at Austin Center Blvd, Austin, TX

2009021, Aug 27, 2009

Apr 2, 2009

12/417496

Mark B. CHANDLER - Austin TX, US
Michael D. SPAIN - Austin TX, US
James MAPES - Austin TX, US
George RODGERS - Austin TX, US

G01N 33/53, C12Q 1/00, C12Q 1/48

435 71, 435 4, 435 15

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL--beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

2007000, Jan 4, 2007

Jun 27, 2006

11/475249

Mark Chandler - Austin TX, US
Michael Spain - Austin TX, US
James Mapes - Austin TX, US
George Rodgers - Austin TX, US

G01N 33/53, C12Q 1/37

435007100, 435023000

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

2007023, Oct 11, 2007

Jan 9, 2007

11/651954

Mark Chandler - Austin TX, US
George Rodgers - Austin TX, US

G06Q 10/00, C12M 1/34, A61B 5/00

705002000, 435287100, 600300000

Provided is a Health Assessment Service comprising a marketing function, a testing function, an evaluation function, and a reporting function and a method of providing the Health Assessment Service. Also provided is a method of diagnosing a condition comprising measuring levels of biomarkers for the condition at a first and second time and comparing the change in levels of biomarkers to reference change values for the condition.